Business
HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan
HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan ...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n \n \n \n HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n \n Public reimbursement for Vascepa is now available in\n \n Ontario\n \n ,\n \n Quebec\n \n ,\n \n British Columbia\n \n ,\n \n Saskatchewan\n \n ,\n \n New Brunswick\n \n ,\n \n Northwest Territories\n \n , Veterans Affairs and for the Non-Insured Health Benefits (NIHB) program for First Nations and Inuit peoples.\n \n \n \n \n \n \n Approximately 14% of all Canadians live in\n \n British Columbia\n \n \n 1\n \n .\n \n \n \n \n \n \n Pacific Blue Cross,\n \n British Columbia's\n \n largest private health plan, also expected to reimburse Vascepa starting in February.\n \n \n \n \n \n \n \n TORONTO\n \n \n ,\n \n \n Feb. 6, 2024\n \n \n /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that it has entered into a Product Listing Agreement (\"PLA\") with the province of\n \n British Columbia\n \n (\"BC\"), for the listing and public reimbursement of Vascepa (icosapent ethyl). The PLA with BC PharmaCare is effective\n \n February 6, 2024\n \n .\n \n \n Under the terms of the PLA, Vascepa will be reimbursed as a Special Authority product by BC PharmaCare for the secondary prevention of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with established cardiovascular disease and elevated triglycerides.\n \n \n The PLA with BC PharmaCare also paves the way for Vascepa to be reimbursed by Pacific Blue Cross, which provides healthcare benefits for approximately 40%\n \n 2\n \n of the privately insured lives in BC. The Pacific Blue Cross reimbursement process for Vascepa is near completion and is also expected to take effect this month.\n \n \n \"The Product Listing Agreement with BC Ph...